Andrew R. Colin
Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory BoardProf. Dr. Andrew R. Colin, MD, serves as a Professor of Pediatrics. Prof. Dr. Colin serves as Director of the Division of Pediatric Pulmonology at Miller School of Medicine, University of Miami. He served as Associate-Chief of a Technion-affiliated Department of Pediatrics in Haifa, Israel. In 1990 he joined the Faculty of Children`s Hospital Boston at Harvard Medical School. He served as Clinical Director of the Division of Respiratory Diseases and also served as Associate Professor at Harvard Medical School. He also served at Children`s Hospital, Boston. He serves as a Member of Medical Advisory Board of EarlySense Ltd. He serves as Member of Scientific Advisory Board at Beyond Air, Inc. (formerly known as AIT Therapeutics, Inc.) since 2013 and served as Chief Medical Officer since December 1, 2021 since March 27, 2023 and is its Senior Medical Director Global Clinical Leadership since March 27, 2023. His expertise includes: asthma, cystic fibrosis, structural and functional development of the respiratory system and related problems including lung diseases of prematurity, pediatric bronchoscopy and more. He participated in research and teaching and received the Klaus Peter International Teaching Award of Harvard Medical School and was the first recipient of the Andrew A. Colin Teaching Award. He is certified by the American Board of Pediatrics in Pediatrics and Pediatric Pulmonology. He was one of the early participants in the studies for the first CF drug, DNase. As a member of the North American Scientific Advisory Board of the Epidemiology Study of Cystic Fibrosis that was established by Genentech following the DNase studies, he participated in the creation of the first major database for all CF patients in the United States and the basis of multiple subsequent studies. In recent years, his focus has been on nontuberculous mycobacteria (NTM) lung infection, and he was the first to report successful treatment with nebulized amikacin for Mycobacterium abscessus in CF patients. He has participated in over 20 studies in his field including ones sponsored by the NIH, Genentech, GlaxoSmithKline and the Cystic Fibrosis Foundation's Therapeutic Development Network. He has authored or co-authored over 80 peer-reviewed publications, as well as multiple reviews. He received his MD at Technion-Israel Institute of Technology, Haifa, Israel in 1976 and completed his pediatric training in hospitals related to that medical school. He trained in Pediatric Pulmonology and Pediatric Intensive Care at Hadassah Hospital in Jerusalem and subsequently at Children`s Hospital Boston, Harvard Medical School.
Positions
- Company NameBeyond Air, Inc.Stock CodeXAIRPositionSenior Medical Director Global Clinical Leadership & Member of Scientific Advisory BoardColleagues
